News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

WED Foundation and XenoPort, Inc. (XNPT) Announce Launch of New “Patient Odyssey” Survey Assessing Day-to-Day Impact of RLS/WED on Both Patients and Loved Ones


9/26/2013 9:52:48 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCHESTER, Minn. & SANTA CLARA, Calif.--(BUSINESS WIRE)--The Willis-Ekbom Disease (WED) Foundation and XenoPort, Inc. (Nasdaq: XNPT) announced today that they have launched a new “Patient Odyssey” survey, aimed at measuring the challenges of long-term disease management, quality of life (QoL) impact and emotional burden associated with restless legs syndrome/Willis-Ekbom Disease (RLS/WED) among patients, as well as the impact of the disease on relationships with spouses or partners. The survey kicks off during this year’s National RLS/WED Awareness Week, dedicated to the continuation of education that improves diagnosis and treatment of the disease.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES